肠道菌群调控体重、脂质代谢及胰岛素敏感性的机制(综述)
创作:楸楸 审核:szx 01月01日
  • 肠道菌群通过调节能量的提取、处理及贮存、白色脂肪组织褐变、代谢产生吲哚调节microRNA等方式调控体重;
  • 肠道菌群可通过胆汁酸、短链脂肪酸等代谢产物以影响脂质的吸收与清除,从而调控脂质代谢;
  • 肠道菌群衍生的代谢产物,包括丙酸咪唑、色氨酸衍生代谢产物、吲哚、犬尿氨酸、5-羟色胺、支链氨基酸、短链脂肪酸可影响胰岛素抵抗;
  • 靶向调控肠道菌群及其代谢产物、限制热量摄入、间歇性禁食等手段可改善代谢。
主编推荐语
szx
肠道菌群的变化与肥胖及2型糖尿病相关。来自Gastroenterology上发表的一篇综述文章,详细介绍了肠道菌群调控体重、脂质代谢及胰岛素抵抗的机制,并讨论了通过靶向调控菌群、饮食干预等方式改善代谢疾病的可能。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gastroenterology [IF:17.373]

Metabolism and Metabolic Disorders and the Microbiome: The intestinal microbiota associated with obesity, lipid metabolism and metabolic health: pathophysiology and therapeutic strategies

代谢、代谢紊乱与菌群:与肥胖、脂质代谢和代谢健康相关的肠道菌群:病理生理学和治疗策略

10.1053/j.gastro.2020.10.057

2020-11-26, Review

Abstract & Authors:展开

Abstract:收起
Changes in the intestinal microbiome have been associated with obesity and type 2 diabetes, in epidemiological studies and studies of the effects of fecal transfer in germ-free mice. We review the mechanisms by which alterations in the intestinal microbiome contribute to development of metabolic diseases, and recent advances, such as the effects of the microbiome on lipid metabolism. Strategies have been developed to modify the intestinal microbiome and reverse metabolic alterations, which might be used as therapies. We discuss approaches that have shown effects in mouse models of obesity and metabolic disorders, and how these might be translated to humans to improve metabolic health.

First Authors:
Judith Aron-Wisnewsky

Correspondence Authors:
Judith Aron-Wisnewsky,Karine Clément

All Authors:
Judith Aron-Wisnewsky,Moritz V Warmbrunn,Max Nieuwdorp,Karine Clément

评论